GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
-4.32%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$454M
AUM Growth
+$454M
(+18%)
Cap. Flow
+$83.2M
Cap. Flow
% of AUM
18.35%
Top 10 Holdings %
Top 10 Hldgs %
63.36%
Holding
41
New
6
Increased
14
Reduced
5
Closed
5
Top Buys
| 1 |
TherapeuticsMD
TXMD
|
$18.9M |
| 2 |
TRVN
Trevena, Inc.
TRVN
|
$17.6M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$14.5M |
| 4 |
Neurocrine Biosciences
NBIX
|
$13.8M |
| 5 |
MACK
Merrimack Pharmaceuticals, Inc.
MACK
|
$10.4M |
Top Sells
| 1 |
DERM
Dermira, Inc.
DERM
|
$17.1M |
| 2 |
Vanda Pharmaceuticals
VNDA
|
$11.1M |
| 3 |
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
|
$8.82M |
| 4 |
PLXP
PLx Pharma Inc. Common Stock
PLXP
|
$2.59M |
| 5 |
PDLI
PDL BioPharma, Inc.
PDLI
|
$2.16M |
Sector Composition
| 1 | Healthcare | 87.1% |
| 2 | Technology | 1.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ADMS
1
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $44M | 9.03% | 2,601,351 | – | – |
|
|
FOMX
2
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $33.3M | 6.84% | 3,000,000 +230,575 | +8% | +$2.56M |
|
|
3
Vanda Pharmaceuticals
VNDA
$279M
| $32.1M | 6.59% | 2,010,000 -696,134 | -26% | -$11.1M |
|
|
SGYP
4
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
| $30.3M | 6.22% | 4,973,509 -1,448,723 | -23% | -$8.82M |
|
|
ZGNX
5
DELISTED
Zogenix, Inc.
ZGNX
| $29.7M | 6.09% | 2,440,959 | – | – |
|
|
6
Neurocrine Biosciences
NBIX
$13.8B
| $29M | 5.96% | 750,000 +355,920 | +90% | +$13.8M |
|
7
Enanta Pharmaceuticals
ENTA
$180M
| $27.7M | 5.7% | 828,253 +38,253 | +5% | +$1.28M |
|
|
RXDX
8
DELISTED
Ignyta, Inc.
RXDX
| $21.2M | 4.36% | 4,000,000 +524,773 | +15% | +$2.78M |
|
|
MACK
9
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $20.4M | 4.19% | 5,000,000 +2,557,841 | +105% | +$10.4M |
|
|
AVXS
10
DELISTED
AveXis, Inc. Common Stock
AVXS
| $19.7M | 4.05% | 413,179 +32,084 | +8% | +$1.53M |
|
|
SAGE
11
DELISTED
Sage Therapeutics
SAGE
| $19.7M | 4.05% | 385,683 +120,790 | +46% | +$6.17M |
|
|
12
TherapeuticsMD
TXMD
$12.8M
| $18.9M | 3.88% | +3,276,010 | New | +$18.9M |
|
|
TRVN
13
DELISTED
Trevena, Inc.
TRVN
| $17.6M | 3.62% | +3,000,650 | New | +$17.6M |
|
|
CLCD
14
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
| $15.9M | 3.27% | 437,865 +37,865 | +9% | +$1.38M |
|
|
GBT
15
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $14.5M | 2.97% | +1,000,000 | New | +$14.5M |
|
|
DBVT
16
DBV Technologies
DBVT
$264M
| $13M | 2.67% | 370,000 +238,548 | +181% | +$8.38M |
|
17
Apyx Medical
APYX
$75.3M
| $11M | 2.25% | 3,055,000 +375,000 | +14% | +$1.35M |
|
18
Rocket Pharmaceuticals
RCKT
$354M
| $9.15M | 1.88% | 1,500,000 +1,405,923 | +1,494% | +$8.58M |
|
19
Acadia Pharmaceuticals
ACAD
$4.38B
| $7.79M | 1.6% | +270,000 | New | +$7.79M |
|
|
CNXR
20
DELISTED
Connecture, Inc.
CNXR
| $6.93M | 1.42% | 4,127,232 | – | – |
|
|
VIRX
21
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $5.57M | 1.14% | 1,537,873 +474,300 | +45% | +$1.72M |
|
|
MYOV
22
DELISTED
Myovant Sciences Ltd.
MYOV
| $4.35M | 0.89% | +350,000 | New | +$4.35M |
|
|
MRTX
23
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $4.13M | 0.85% | 870,261 +642,604 | +282% | +$3.05M |
|
|
OCRX
24
DELISTED
Ocera Therapeutics, Inc.
OCRX
| $4.12M | 0.85% | 1,963,777 | – | – |
|
|
DERM
25
DELISTED
Dermira, Inc.
DERM
| $3.46M | 0.71% | 114,080 -565,323 | -83% | -$17.1M |
|